Patent · US Active

Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy

US10081679B2 · kind B2 · utility

7Cited by
12References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 25, 2014
Grant dateSep 25, 2018
Priority date
Expiry dateNov 25, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.